Healthcare provider profile · identity verified

Sarah Kent, MD

Family Practice · CROSSROADS, TX · NPI 1457573222

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	419	135
Levothyroxine Sodium	Levothyroxine Sodium	338	100
Amlodipine Besylate	Amlodipine Besylate	287	99
Rosuvastatin Calcium	Rosuvastatin Calcium	199	71
Losartan Potassium	Losartan Potassium	196	66
Lisinopril	Lisinopril	184	59
Hydrochlorothiazide	Hydrochlorothiazide	134	43
Gabapentin	Gabapentin	116	45
Metformin Hcl	Metformin Hcl	106	34
Metoprolol Succinate	Metoprolol Succinate	106	38
Pravastatin Sodium	Pravastatin Sodium	106	30
Alendronate Sodium	Alendronate Sodium	103	27
Montelukast Sodium	Montelukast Sodium	100	29
Pantoprazole Sodium	Pantoprazole Sodium	94	33
Sertraline Hcl	Sertraline Hcl	88	31
Trazodone Hcl	Trazodone Hcl	85	26
Baclofen	Baclofen	83	35
Omeprazole	Omeprazole	81	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	79	26
Meloxicam	Meloxicam	73	26
Duloxetine Hcl	Duloxetine Hcl	70	21
Metformin Hcl Er	Metformin Hcl	68	23
Carvedilol	Carvedilol	66	24
Metoprolol Tartrate	Metoprolol Tartrate	65	25
Simvastatin	Simvastatin	63	19
Allopurinol	Allopurinol	61	19
Albuterol Sulfate Hfa	Albuterol Sulfate	58	43
Furosemide	Furosemide	58	25
Potassium Chloride	Potassium Chloride	54	24
Tizanidine Hcl	Tizanidine Hcl	53	20
Venlafaxine Hcl Er	Venlafaxine Hcl	51	13
Olmesartan Medoxomil	Olmesartan Medoxomil	50	14
Synthroid	Levothyroxine Sodium	50	14
Tramadol Hcl	Tramadol Hcl	49	20
Prednisone	Prednisone	46	40
Escitalopram Oxalate	Escitalopram Oxalate	45	18
Fluticasone Propionate	Fluticasone Propionate	45	21
Hydralazine Hcl	Hydralazine Hcl	45	15
Celecoxib	Celecoxib	44	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	14
Eliquis	Apixaban	43	12
Famotidine	Famotidine	42	15
Ozempic	Semaglutide	40	15
Pioglitazone Hcl	Pioglitazone Hcl	39	suppressed
Atenolol	Atenolol	38	12
Doxycycline Hyclate	Doxycycline Hyclate	37	35
Citalopram Hbr	Citalopram Hydrobromide	36	11
Finasteride	Finasteride	36	suppressed
Mounjaro	Tirzepatide	36	suppressed
Methylprednisolone	Methylprednisolone	35	32
Spironolactone	Spironolactone	34	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	29
Lovastatin	Lovastatin	33	11
Nifedipine Er	Nifedipine	33	13
Nystatin	Nystatin	33	17
Trulicity	Dulaglutide	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	24
Ondansetron Odt	Ondansetron	30	13
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Estradiol	Estradiol	29	12
Glimepiride	Glimepiride	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	27	13
Jardiance	Empagliflozin	27	suppressed
Solifenacin Succinate	Solifenacin Succinate	27	12
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	26	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	24	suppressed
Valsartan	Valsartan	24	suppressed
Acyclovir	Acyclovir	23	suppressed
Clonidine Hcl	Clonidine Hcl	22	12
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Fenofibrate	Fenofibrate	22	suppressed
Fluconazole	Fluconazole	22	16
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	14
Sucralfate	Sucralfate	21	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Cefdinir	Cefdinir	19	17
Diclofenac Sodium	Diclofenac Sodium	19	11
Ezetimibe	Ezetimibe	19	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	16
Myrbetriq	Mirabegron	19	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	19	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	19	suppressed
Alprazolam	Alprazolam	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	15
Buspirone Hcl	Buspirone Hcl	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Azithromycin	Azithromycin	16	16
Estradiol (Once Weekly)	Estradiol	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Glipizide Er	Glipizide	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Glipizide	Glipizide	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Telmisartan	Telmisartan	14	suppressed
Clonazepam	Clonazepam	13	suppressed
Liothyronine Sodium	Liothyronine Sodium	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	12	suppressed
Bydureon Bcise	Exenatide Microspheres	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Cefuroxime	Cefuroxime Axetil	11	11
Irbesartan	Irbesartan	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error